A novel player in cellular hypertrophy: G iβγ/PI3K-dependent activation of the RacGEF TIAM-1 is required for α 1-adrenoceptor induced hypertrophy in neonatal rat cardiomyocytes

Journal of Molecular and Cellular Cardiology

Volumn 53, Issue 2, 2012, Pages 165-175

  Vettel, Christiane ^a,b   Wittig, Karola ^a   Vogt, Andreas ^a   Wuertz, Christina M ^b   El Armouche, Ali ^b   Lutz, Susanne ^b   Wieland, Thomas ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

Author keywords

1 Adrenoceptor; Cellular hypertrophy; Exchange factor; Gi protein; Guanine nucleotide; Neonatal rat cardiomyocytes; P21 activated kinase; Rac1; RhoGTPases; Tiam1

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR STIMULATING AGENT; ALPHA 1A ADRENERGIC RECEPTOR SUBTYPE GIBETAGAMMA; ATRIAL NATRIURETIC FACTOR; GUANINE NUCLEOTIDE EXCHANGE FACTOR; P21 ACTIVATED KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; RAC1 PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BINDING SITE; CELL GROWTH; CELL SIZE; CONTROLLED STUDY; HEART MUSCLE CELL; HYPERTROPHY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; PROTEIN SYNTHESIS; PROTEIN TARGETING; RAT;

ADRENERGIC ALPHA-1 RECEPTOR AGONISTS; AMINOQUINOLINES; ANIMALS; ANIMALS, NEWBORN; CARDIOMEGALY; CELLS, CULTURED; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; GTP-BINDING PROTEIN ALPHA SUBUNITS, GI-GO; GUANINE NUCLEOTIDE EXCHANGE FACTORS; IMMUNOBLOTTING; MYOCYTES, CARDIAC; NEOPLASM PROTEINS; P21-ACTIVATED KINASES; PHENYLEPHRINE; PHOSPHATIDYLINOSITOL 3-KINASES; PYRIMIDINES; RAC1 GTP-BINDING PROTEIN; RATS; RECEPTORS, ADRENERGIC, ALPHA-1; SIGNAL TRANSDUCTION;

RATTUS;

EID: 84862839653     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2012.04.015     Document Type: Article

References (58)

1. Hill J.A., Olson E.N. Cardiac plasticity. N Engl J Med 2008, 358:1370-1380.
2. Triposkiadis F., Karayannis G., Giamouzis G., Skoularigis J., Louridas G., Butler J. The sympathetic nervous system in heart failure physiology, pathophysiology, and clinical implications. J Am Coll Cardiol 2009, 54:1747-1762.
3. 1-adrenergic receptor transgenic mice. Proc Natl Acad Sci U S A 1999, 96:7059-7064.
4. 1B-adrenergic receptor in transgenic mice induces cardiac hypertrophy. Proc Natl Acad Sci U S A 1994, 91:10109-10113.
5. Lohse M.J., Engelhardt S., Eschenhagen T. What is the role of β-adrenergic signaling in heart failure?. Circ Res 2003, 93:896-906.
6. 1-adrenergic drive in pathological remodelling. Cardiovasc Res 2008, 77:452-462.
7. 1-Adrenergic receptor subtypes in nonfailing and failing human myocardium. Circ Heart Fail 2009, 2:654-663.
8. 1-Adrenergic receptors: targets for agonist drugs to treat heart failure. J Mol Cell Cardiol 2011, 51:518-528.
9. 1A-adrenergic receptor overexpression induces enhanced cardiac contractility but not hypertrophy. Circ Res 2001, 89:343-350.
10. 1B-adrenergic receptor defect in mice. Circulation 2002, 105:1700-1707.
11. 1B-adrenergic receptors after pressure overload in mouse hearts. Am J Physiol 2000, 279:H1079-H1086.
12. 1A-adrenergic receptors in neonatal cardiac myocytes is sufficient to cause hypertrophy and differential regulation of alpha1-adrenergic receptor subtype mRNAs. J Mol Cell Cardiol 1998, 30:1515-1523.
13. 1A-adrenergic receptor subtype mediates biochemical, molecular, and morphologic features of cultured myocardial cell hypertrophy. J Biol Chem 1993, 26:15374-15380.
14. 1-adrenergic receptor-induced cardiac hypertrophy. Circ Res 2002, 91:961-969.
15. 1-adrenergic, endothelin-1 and thrombin-sensitive protease-activated receptors. Cell Signal 2005, 17:655-664.
16. Clerk A., Pham F.H., Fuller S.J., Sahai E., Aktories K., Marais R., et al. Regulation of mitogen-activated protein kinases in cardiac myocytes through the small G protein Rac1. Mol Cell Biol 2001, 21:1173-1184.
17. Miyamoto S., Del Re D.P., Xiang S.Y., Zhao X., Florholmen G., Brown J.H. Revisited and revised: is RhoA always a villain in cardiac pathophysiology?. J Cardiovasc Transl Res 2010, 3:330-343.
18. Sah V.P., Minamisawa S., Tam S.P., Wu T.H., Dorn G.W., Ross J., et al. Cardiac-specific overexpression of RhoA results in sinus and atrioventricular nodal dysfunction and contractile failure. J Clin Invest 1999, 103:1627-1634.
19. Xiang S.Y., Vanhoutte D., Del Re D.P., Purcell N.H., Ling H., Banerjee I., et al. RhoA protects the mouse heart against ischemia/reperfusion injury. J Clin Invest 2011, 121:3269-3276.
20. Pracyk J.B., Tanaka K., Hegland D.D., Kim K.S., Sethi R., Rovira I.I., et al. A requirement for the rac1 GTPase in the signal transduction pathway leading to cardiac myocyte hypertrophy. J Clin Invest 1998, 102:929-937.
21. Satoh M., Ogita H., Takeshita K., Mukai Y., Kwiatkowski D.J., Liao J.K. Requirement of Rac1 in the development of cardiac hypertrophy. Proc Natl Acad Sci U S A 2006, 103:7432-7437.
22. Sussman M.A., Welch S., Walker A., Klevitsky R., Hewett T.E., Price R.L., et al. Altered focal adhesion regulation correlates with cardiomyopathy in mice expressing constitutively active rac1. J Clin Invest 2000, 105:875-886.
23. Lu H., Fedak P.W., Dai X., Du C., Zhou Y.Q., Henkelman M., et al. Integrin-linked kinase expression is elevated in human cardiac hypertrophy and induces hypertrophy in transgenic mice. Circulation 2006, 114:2271-2279.
24. Rossman K.L., Der C.J., Sondek J. GEF means go: turning on RHO GTPases with guanine nucleotide-exchange factors. Nat Rev Mol Cell Biol 2005, 6:167-180.
25. Loirand G., Scalbert E., Bril A., Pacaud P. Rho exchange factors in the cardiovascular system. Curr Opin Pharmacol 2008, 8:174-180.
26. Will R.D., Eden M., Just S., Hansen A., Eder A., Frank D., et al. Myomasp/LRRC39, a heart- and muscle-specific protein, is a novel component of the sarcomeric M-band and is involved in stretch sensing. Circ Res 2010, 107:1253-1264.
27. 2+ sensitivity in ventricular myocytes. Circ Res 2007, 100:864-873.
28. He B., Weber G.F. Synergistic activation of the CMV promoter by NFκB P50 and PKG. Biochem Biophys Res Commun 2004, 321:13-20.
29. Prosch S., Wendt C.E., Reinke P., Priemer C., Oppert M., Kruger D.H., et al. A novel link between stress and human cytomegalovirus (HCMV) infection: sympathetic hyperactivity stimulates HCMV activation. Virology 2000, 272:357-365.
30. Demidenko Z.N., Blagosklonny M.V. Quantifying pharmacologic suppression of cellular senescence: prevention of cellular hypertrophy versus preservation of proliferative potential. Aging 2009, 1:1008-1016.
31. i-coupled receptors from Rac1 to RhoA activation. Cell Signal 2007, 19:1229-1237.
32. 1 receptor, PI3 kinase, Tiam1/Rac1, and α-actinin. FASEB J 2005, 19:1646-1656.
33. Gao Y., Dickerson J.B., Guo F., Zheng J., Zheng Y. Rational design and characterization of a Rac GTPase-specific small molecule inhibitor. Proc Natl Acad Sci U S A 2004, 101:7618-7623.
34. Arias-Romero L.E., Chernoff J. A tale of two Paks. Biol Cell 2008, 100:97-108.
35. Deacon S.W., Beeser A., Fukui J.A., Rennefahrt U.E., Myers C., Chernoff J., et al. An isoform-selective, small-molecule inhibitor targets the autoregulatory mechanism of p21-activated kinase. Chem Biol 2008, 15:322-331.
36. Takeishi Y., Huang Q., Abe J., Che W., Lee J.D., Kawakatsu H., et al. Activation of mitogen-activated protein kinases and p90 ribosomal S6 kinase in failing human hearts with dilated cardiomyopathy. Cardiovasc Res 2002, 53:131-137.
37. Yund E.E., Hill J.A., Keller R.S. Hic-5 is required for fetal gene expression and cytoskeletal organization of neonatal cardiac myocytes. J Mol Cell Cardiol 2009, 47:520-527.
38. Lorenz K., Schmitt J.P., Schmitteckert E.M., Lohse M.J. A new type of ERK1/2 autophosphorylation causes cardiac hypertrophy. Nat Med 2009, 15:75-83.
39. 1-adrenergic stimulation. Mol Pharmacol 2007, 71:799-806.
40. Adams H.C., Chen R., Liu Z., Whitehead I.P. Regulation of breast cancer cell motility by T-cell lymphoma invasion and metastasis-inducing protein. Breast Cancer Res 2010, 12:R69.
41. Pegtel D.M., Ellenbroek S.I., Mertens A.E., van der Kammen R.A., de Rooij J., Collard J.G. The Par-Tiam1 complex controls persistent migration by stabilizing microtubule-dependent front-rear polarity. Curr Biol 2007, 17:1623-1634.
42. Gonzalez E., Kou R., Michel T. Rac1 modulates sphingosine 1-phosphate-mediated activation of phosphoinositide 3-kinase/Akt signaling pathways in vascular endothelial cells. J Biol Chem 2006, 281:3210-3216.
43. Wuertz C.M., Lorincz A., Vettel C., Thomas M.A., Wieland T., Lutz S. p63RhoGEF-a key mediator of angiotensin II-dependent signaling and processes in vascular smooth muscle cells. FASEB J 2010, 24:4865-4876.
44. Shibata S., Nagase M., Yoshida S., Kawarazaki W., Kurihara H., Tanaka H., et al. Modification of mineralocorticoid receptor function by Rac1 GTPase: implication in proteinuric kidney disease. Nat Med 2008, 14:1370-1376.
45. 2+ flux modification with altered regulatory protein phosphorylation in cardiac myocytes. Am J Physiol 2009, 296:C47-C58.
46. Beeser A., Jaffer Z.M., Hofmann C., Chernoff J. Role of group A p21-activated kinases in activation of extracellular-regulated kinase by growth factors. J Biol Chem 2005, 280:36609-36615.
47. Ke Y., Lei M., Solaro R.J. Regulation of cardiac excitation and contraction by p21 activated kinase-1. Prog Biophys Mol Biol 2008, 98:238-250.
48. Mao K., Kobayashi S., Jaffer Z.M., Huang Y., Volden P., Chernoff J., et al. Regulation of Akt/PKB activity by P21-activated kinase in cardiomyocytes. J Mol Cell Cardiol 2008, 44:429-434.
49. Liu W., Zi M., Naumann R., Ulm S., Jin J., Taglieri D.M., et al. Pak1 as a novel therapeutic target for antihypertrophic treatment in the heart. Circulation 2011, 124:2702-2715.
50. Taglieri D.M., Monasky M.M., Knezevic I., Sheehan K.A., Lei M., Wang X., et al. Ablation of p21-activated kinase-1 in mice promotes isoproterenol-induced cardiac hypertrophy in association with activation of Erk1/2 and inhibition of protein phosphatase 2A. J Mol Cell Cardiol 2011, 51:988-996.
51. Suzuki K., Wilkes M.C., Garamszegi N., Edens M., Leof E.B. Transforming growth factor beta signaling via Ras in mesenchymal cells requires p21-activated kinase 2 for extracellular signal-regulated kinase-dependent transcriptional responses. Cancer Res 2007, 67:3673-382.
52. Sbroggio M., Carnevale D., Bertero A., Cifelli G., De Blasio E., Mascio G., et al. IQGAP1 regulates ERK1/2 and AKT signalling in the heart and sustains functional remodelling upon pressure overload. Cardiovasc Res 2011, 91:456-464.
53. Sbroggio M., Bertero A., Velasco S., Fusella F., De Blasio E., Bahou W.F., et al. ERK1/2 activation in heart is controlled by melusin, focal adhesion kinase and the scaffold protein IQGAP1. J Cell Sci 2011, 124:3515-3524.
54. Usatyuk P.V., Gorshkova I.A., He D., Zhao Y., Kalari S.K., Garcia J.G., et al. Phospholipase D-mediated activation of IQGAP1 through Rac1 regulates hyperoxia-induced p47phox translocation and reactive oxygen species generation in lung endothelial cells. J Biol Chem 2009, 284:15339-15352.
55. Yamaguchi N., Chakraborty A., Pasek D.A., Molkentin J.D., Meissner G. Dysfunctional ryanodine receptor and cardiac hypertrophy: role of signaling molecules. Am J Physiol 2011, 300:H2187-H2195.
56. Richards S.A., Dreisbach V.C., Murphy L.O., Blenis J. Characterization of regulatory events associated with membrane targeting of p90 ribosomal S6 kinase 1. Mol Cell Biol 2001, 21:747074-747080.
57. i signals. Mol Cell Biol 2000, 20:6837-6848.
58. Heineke J., Molkentin J.D. Regulation of cardiac hypertrophy by intracellular signalling pathways. Nat Rev Mol Cell Biol 2006, 7:589-600.